Generated by AI
Damora Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for hematologic disorders, with an emphasis on mutant calreticulin-driven myeloproliferative neoplasms. Its current pipeline centers on DMR-001, an investigational monoclonal antibody therapy for essential thrombocythemia, alongside DMR-002 and DMR-003, which are designed to broaden coverage across mutCALR-driven disease biology. The company also develops GB3226, a small-molecule inhibitor targeting ENL-YEATS and FLT3 for acute myeloid leukemia. Damora Therapeutics concentrates on advancing targeted, disease-modifying therapies for blood cancers and related marrow disorders through a research-driven clinical development model. Founded in 2011 and headquartered in Waltham, Massachusetts, Damora Therapeutics operates in the biopharmaceutical sector as a developer of specialized therapies for patients with significant unmet medical needs.
WebsiteBuilding 23
Waltham, MA, 02453
United States
Summary of Apr 27's posts. Generated by AI.
Summary of Feb 13's posts. Generated by AI.
Summary of Feb 13's posts. Generated by AI.
Investors talking about GLTO also mention these. Each card shows that asset’s own numbers for the past 24 hours.